ResearchMoz

Dyslexia Global Clinical Trials Review, H1, 2013

GlobalData
Published Date » 2013-04-12
No. Of Pages » 59
 Dyslexia Global Clinical Trials Review, H1, 2013  Summary   GlobalData's clinical trial report, Dyslexia Global Clinical Trials Review, H1, 2013" provides data on the Dyslexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyslexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. 
   
 The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyslexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house...
Table of Content

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Dyslexia 5
Symptoms of dyslexia are: 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by BRIC Nations 13
Clinical Trials by G7 Nations 14
Clinical Trials in G7 Nations by Trial Status 15
Clinical Trials by E7 Nations 16
Clinical Trials in E7 Nations by Trial Status 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Unaccomplished Trials of Dyslexia 21
Subjects Recruited Over a Period of Time 22
Prominent Sponsors 23
Prominent Drug Comparison 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Eli Lilly and Company 26
Clinical Trial Overview of Eli Lilly and Company 26
Clinical Trial Overview of Top Universities / Institutes / Hospitals 27
University Hospital, Tours 27
Clinical Trial Overview of University Hospital, Tours 27
Macquarie University 28
Clinical Trial Overview of Macquarie University 28
University of Tasmania 29
Clinical Trial Overview of University of Tasmania 29
University of Munster 30
Clinical Trial Overview of University of Munster 30
McGill University 31
Clinical Trial Overview of McGill University 31
University of Oxford 32
Clinical Trial Overview of University of Oxford 32
Vanderbilt University 33
Clinical Trial Overview of Vanderbilt University 33
Rabin Medical Center 34
Clinical Trial Overview of Rabin Medical Center 34
Five Key Clinical Profiles 35

Appendix 57
Abbreviations 57
Definitions 57
Research Methodology 58
Secondary Research 58
About GlobalData 59
Contact Us 59
Disclaimer 59
Source 59

List of Tables


Dyslexia Therapeutics Market, Global, Clinical Trials by Zone, 2013* 6
Dyslexia Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 7
Dyslexia Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 8
Dyslexia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2013* 9
Dyslexia Therapeutics Clinical Trials, Europe, Top Countries, 2013* 10
Dyslexia Therapeutics Clinical Trials, North America, Top Countries, 2013* 11
Dyslexia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2013* 12
Dyslexia Therapeutics Clinical Trials, BRIC Countries, 2013* 13
Dyslexia Therapeutics Clinical Trials, G7 Countries, 2013* 14
Dyslexia Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 15
Dyslexia Therapeutics Clinical Trials, E7 Countries, 2013* 16
Dyslexia Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 17
Dyslexia Therapeutics Market, Global, Clinical Trials by Phase, 2013* 18
Dyslexia Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 19
Dyslexia Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 20
Dyslexia Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 21
Dyslexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 22
Dyslexia Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 24
Dyslexia Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 25
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2013* 26
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Tours, 2013* 27
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Macquarie University, 2013* 28
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Tasmania, 2013* 29
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Munster, 2013* 30
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by McGill University, 2013* 31
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2013* 32
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2013* 33
Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rabin Medical Center, 2013* 34

List of Figures


Dyslexia Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 6
Dyslexia Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 7
Dyslexia Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 8
Dyslexia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2013* 9
Dyslexia Therapeutics Clinical Trials, Europe, Top Countries (%), 2013* 10
Dyslexia Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 11
Dyslexia Therapeutics Clinical Trials, G7 Countries (%), 2013* 14
Dyslexia Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 15
Dyslexia Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 18
Dyslexia Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 19
Dyslexia Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 20
Dyslexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 22
Dyslexia Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 23
Dyslexia Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 25
GlobalData Methodology 58

Upcoming Reports:

Flexitanks Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
A flexitank is a large plastic bag, fitted with a loading and discharge valve. Prior to loading, the flexi-tank bag is laid out into a box container. Unlike the tank container, which is re-used repeatedly, the flexitank is designed for one trip. The empty contaminated bag must be disposed in an approved waste facility. Certain materials can be incinerated and others might be suitable for shredding in preparation for recycling. Currently, containers are tested and approved by issue of a safety certificate (CSC); however, flexitanks are tested independently of the container. At present,...
Greece: cotton seed oil market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the cotton seed oil market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the cotton seed oil market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview...
Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
The generic drugs industry comprises of the manufacture and marketing of certain drugs which have the same active ingredients as the brand-name drugs manufactured by any pharmaceutical company. The major benefit of generic drugs is that the cost of such drugs is much less than that of branded drugs. Generic drugs come under the same governing framework as that of the brand-name drugs. The rationale behind generic drugs is that the patented drugs generally have a patent life of 20 years. However, the patent life of such drugs begins from the clinical trials and thus their commercial...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...